Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
April 17, 2024

Orladeyo gains approval in Brazil for HAE prevention

Brazil's Health Regulatory Agency (ANVISA) has approved Orladeyo (berotralstat) for the prevention of hereditary angioedema (HAE) attacks in adult and pediatric patients aged 12 and older, offering a new oral treatment for those suffering from this genetic disorder.

Brazil's Health Regulatory Agency (ANVISA) approves Orladeyo. Credit: Mustafa shehadeh from Pixabay.